A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache

Trial Profile

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Nov 2017

At a glance

  • Drugs Fremanezumab (Primary) ; Fremanezumab (Primary)
  • Indications Cluster headache
  • Focus Therapeutic Use
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 02 Nov 2017 Planned End Date changed from 30 Oct 2018 to 6 Nov 2018.
    • 02 Nov 2017 Planned primary completion date changed from 28 Sep 2018 to 9 Oct 2018.
    • 13 Jan 2017 Planned number of patients changed from 171 to 300.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top